Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Automate Your Wheel Strategy on CVKD
With Tiblio's Option Bot, you can configure your own wheel strategy including CVKD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CVKD
- Rev/Share 0.0
- Book/Share 1.338
- PB 5.9342
- Debt/Equity 0.0
- CurrentRatio 3.016
- ROIC -5.3656
- MktCap 16477977.0
- FreeCF/Share -5.7871
- PFCF -1.393
- PE -1.1282
- Debt/Assets 0.0
- DivYield 0
- ROE -2.7952
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Cadrenal's Quiet Expansion Play Is Starting to Get Loud
Published: December 12, 2025 by: Accesswire
Sentiment: Neutral
PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ: CVKD ) entered the back half of the year with a calm, almost surgical approach to building out its foundation. While most microcaps lean on noise to stay visible, Cadrenal has let its work do the lifting.
Read More
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market
Published: December 12, 2025 by: Accesswire
Sentiment: Neutral
PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread by the market. Yes, the Company is intentionally narrowly focused.
Read More
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
Published: December 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D.
Read More
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Published: August 11, 2025 by: Business Wire
Sentiment: Neutral
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal Therapeutics reports on Second Quarter 2025 financial results and provides corporate update on strategic clinical trial plans.
Read More
About Cadrenal Therapeutics, Inc. Common Stock (CVKD)
- IPO Date 2023-01-20
- Website https://www.cadrenal.com
- Industry Biotechnology
- CEO Quang X. Pham
- Employees 4